Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
22 sept. 2022 08h30 HE
|
Clearmind Medicine Inc.
Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd. VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Medicine Announces Share-Based Payment for one of the Company's Consultants
16 sept. 2022 16h30 HE
|
Clearmind Medicine Inc.
VANCOUVER, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and...
Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment
24 août 2022 10h24 HE
|
Clearmind Medicine Inc.
The dedicated treatment indicated a significant decrease in cocaine craving in a sub- group that received Clearmind's MEAI VANCOUVER, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc....
Yale’s Department of Psychiatry Chair to Join Clearmind Medicine
21 juin 2022 09h00 HE
|
Clearmind Medicine Inc.
Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board VANCOUVER, June 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,...
Clearmind Medicine Appoints New Chief Financial Officer
15 juin 2022 16h52 HE
|
Clearmind Medicine Inc.
VANCOUVER, June 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of...
Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment
07 juin 2022 08h30 HE
|
Clearmind Medicine Inc.
The dedicated treatment demonstrated a significant decrease in preference for an area associated with cocaine VANCOUVER, June 07, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment
02 juin 2022 07h48 HE
|
Clearmind Medicine Inc.
No dedicated treatment currently available for cocaine addiction VANCOUVER, June 02, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the...
Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India
01 juin 2022 08h11 HE
|
Clearmind Medicine Inc.
The patent was granted by India’s Office of the Controller-General of Patents, Designs and Trademarks VANCOUVER, June 01, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink:...
Clearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorder
26 mai 2022 09h30 HE
|
Clearmind Medicine Inc.
Clearmind aims to initiate clinical trials with CMND-100 by year’s end VANCOUVER, May 26, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF,FSE: CWY0) (“Clearmind” or the...
Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
24 mai 2022 08h30 HE
|
Clearmind Medicine Inc.
Pre-clinical trial based on the proprietary combination demonstrates high safety profile in addition to a significant suppressive effect on alcohol consumption Vancouver, May 24, 2022 ...